Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 18
Treatment-assignment count: 0
Stratification count: 0
gastric cancer · Combination Therapy
RET fusion is flagged as trial selection rising because public trials show inclusion required evidence in 18 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 18
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 13
Common snippets: MSI-H | MSI-H | MSI-H
Threshold label: Moderate
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT05458219 | https://clinicaltrials.gov/study/NCT04933227 | https://clinicaltrials.gov/study/NCT06829797 | https://clinicaltrials.gov/study/NCT04603040 | https://clinicaltrials.gov/study/NCT05836584 | https://clinicaltrials.gov/study/NCT05177133 | https://clinicaltrials.gov/study/NCT06974110 | https://clinicaltrials.gov/study/NCT06250036 | https://clinicaltrials.gov/study/NCT05002686 | https://clinicaltrials.gov/study/NCT05713838 | https://clinicaltrials.gov/study/NCT03935893 | https://clinicaltrials.gov/study/NCT03504397 | https://clinicaltrials.gov/study/NCT07483567 | https://clinicaltrials.gov/study/NCT01630083 | https://clinicaltrials.gov/study/NCT06038396 | https://clinicaltrials.gov/study/NCT06321913 | https://clinicaltrials.gov/study/NCT06962137 | https://clinicaltrials.gov/study/NCT03653507